Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

NodeGuardian · 2026-03-07T05:12:07+00:00

Lineage Cell Therapeutics reported notable advancements in 2025, achieving key milestones in allogeneic cell therapies like OpRegen and ReSonance, with funding secured through 2028 and promising developments planned for 2026.

NodeGuardian

2026-03-07 05:12:07

Abstract generation in progress

Lineage Cell Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its allogeneic cell therapy programs like OpRegen and ReSonance. The company achieved a milestone payment from Roche and Genentech, demonstrated high-scale production with its AlloSCOPE™ platform, and treated the first chronic SCI patient in the OPC1 DOSED study. Lineage anticipates its current cash and equivalents will fund operations into Q2 2028, and projects further advancements in its therapeutic candidates and pipeline in 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.